Clinical outcomes of deferiprone administration (deferiprone) in children with thalassemia who have iron overload in Phetchabun Hospital

Abstract

     Thalassemia anemia is a genetic hematological disease with a very high incidence in Thailand. Iron overload is complication and iron chelation therapy were treated with deferiprone. Objective to compare serum ferritin levels before and after deferiprone administration at 3 months, 6 months and 12 months in iron overloaded thalassemia children and study the side effects of the deferiprone. Methods study of thalassemia pediatric patients aged 2 - 15 years with iron overload that iron chelation theraypy by deferiprone. The population included total of 57 cases of pediatric that visit from January 1, 2017 to December 31, 2022. The data were analyzed by descriptive statistics and inferential statistics, repeated measure ANOVA, with statistical significance set at P-value < 0.05. Children with thalassemia with iron overload that iron chelation theraypy by deferiprone total 57 cases and most of them was beta thalassemia. Need blood transfusions more than 10 per year. The percentile of weight and height prior to deferiprone administration was mostly in the 10 to 90 percentile range. Side effect after administration deferiprone was found include transaninitis, thrombocytopenia, neutropenia, proteinuria, arthralgia, arthritis, nausea and vomiting. The mean serum ferritin levels decreased significantly differently before and after deferriprone administration 6 months and 12 months. The mean serum ferritin level decreased significantly differently before and 6 months after deferriprone deferriprone administration.